Search Results
Mar 28, 2026, 15:15 ET Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
care-seeking adults in the US in 2024, Truveta (data on file). Comorbidities include atherosclerotic cardiovascular disease (ASCVD), type 2 diabetes mellitus (T2DM), dyslipidemia, hypertension, obstructive sleep apnea (OSA).2 Proft F, et al. Nat Rev Rheumatol. 2026 Feb;22(2):132-144.3
More news about: Eli Lilly and Company
Mar 27, 2026, 09:00 ET UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.11. Griffiths CEM, van der Walt JM, Ashcroft DM, et al. The global state of psoriasis disease epidemiology: a workshop report. Br J Dermatol. 2017;177(1):e4-e7.12. BIMZELX® (bimekizumab-bkzx)
More news about: UCB
Mar 26, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
Drug Administration (FDA) has placed a partial clinical hold on the FREEDOM2-DM1 Phase 2 multiple ascending dose (MAD), randomized, placebo-controlled clinical trial of PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1)", stating that "[t]he partial clinical hold questions raised by FDA relate to
More news about: Pomerantz LLP
Mar 24, 2026, 07:00 ET Sweet Victory Gum Helps Type 1 Diabetics Halve Sweets Snacking in Pilot Clinical Trial
24, 2026 /PRNewswire/ -- Results of a new clinical pilot study reveal that chewing Sweet Victory gum could help patients with type 1 diabetes (T1DM) reduce sweet snacking by more than half. The functional chewing gum, formulated with powdered leaves of the Gymnema sylvestre plant was designed
More news about: Sweet Victory
Mar 24, 2026, 03:43 ET DualityBio (9606.HK) Announces 2025 Annual Results
("BICR"), relative to the control arm. This trial is conducted in China to evaluate the efficacy of DB-1303/BNT323 versus T-DM1 in patients with HER2+ unresectable and/or metastatic Breast Cancer ("BC") previously treated with trastuzumab and taxane. Another Phase 3 trial of
More news about: Duality Biotherapeutics, Inc.
Mar 24, 2026, 02:20 ET 映恩生物（9606.HK）公佈2025年度業績
DYNASTY-Breast01（NCT06265428）這一3 期註冊性試驗的中期資料完成審閱，確認該試驗相對於對照組，已達到由盲態獨立中心審閱（BICR）評核的無進展生存期（PFS）主要終點。此項在中國開展的臨床試驗，旨在評估 DB-1303/BNT323 對比 T-DM1，在既往接受過曲妥珠單抗及紫杉烷治療的 HER2 + 不可切除及 / 或轉移性乳腺癌患者中的治療效果。該產品中國 3 期試驗（NCT06265428）針對既往接受過曲妥珠單抗及紫杉烷治療的 HER2 + 不可切除 / 轉移性乳腺癌患者，目前已向 CDE 提交生物製品上市許可申請（BLA），申請處於正式受理審核階段。針對
More news about: Duality Biotherapeutics, Inc.
Mar 23, 2026, 08:00 ET Goldtouch Introduces 2026 Office Keyboard and Mouse Collection
something of this size. It's designed for people who work from more than one place.Goldtouch Wireless Keyboard + Mouse Combo | Part # KM-4660-DMKeyboard and mouse, one 2.4G receiver connecting both. The keyboard handles 2.4G and Bluetooth, and the mouse adds a dedicated DPI button for switching
More news about: Goldtouch
Mar 20, 2026, 10:53 ET University of Phoenix researchers present studies on human-AI collaboration and AI-ready healthcare curriculum at AECT 2026 Online Conference
The research team included Amanda Gabarda, Ed.D., MPH, Jennifer James, Ph.D., Christopher Mosley, DSL, Thomas Sloan, MBA, and Sisay Teketele, DCS, DM, representing University of Phoenix and collaborating institutions. The presenters shared findings from a 2025 research project analyzing the AI-related
More news about: University of Phoenix
Mar 19, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
Drug Administration (FDA) has placed a partial clinical hold on the FREEDOM2-DM1 Phase 2 multiple ascending dose (MAD), randomized, placebo-controlled clinical trial of PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1)", stating that "[t]he partial clinical hold questions raised by FDA relate to
More news about: Pomerantz LLP
Mar 18, 2026, 12:23 ET FTX Recovery Trust to Distribute Approximately $2.2 Billion to Creditors in Fourth Distribution on March 31, 2026
https://cases.ra.kroll.com/FTX/.FTX Digital Markets Ltd. ("FTX DM") will be separately communicating distribution information for customers who have elected to have their claims administered by FTX DM.AdvisorsThe FTX Recovery Trust is represented by Sullivan &
More news about: FTX
Mar 17, 2026, 05:00 ET Tencent Music Entertainment Group Announces Fourth Quarter and Full-Year 2025 Unaudited Financial Results
consumption.Introduced new social features within our music applications to amplify user reach and deepen user engagement. 1) QQ Music launched Weverse DM, onboarding around 170 artists from HYBE and other labels to deepen artist-fan interactions. 2) bubble enhanced its functionality by introducing
More news about: Tencent Music Entertainment Group
Mar 13, 2026, 02:35 ET Aster DM Healthcare receives overwhelmingly positive shareholder and creditors vote for Aster-QCIL merger
voting, Dr. Azad Moopen, Founder Chairman, Aster DM Healthcare, said, "The strong support from our shareholders reflects their confidence in the strategic rationale of this merger and the long-term value it will deliver. By bringing together Aster DM Healthcare and Quality Care India, we are building
More news about: Aster DM Healthcare
Mar 12, 2026, 18:30 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
Drug Administration (FDA) has placed a partial clinical hold on the FREEDOM2-DM1 Phase 2 multiple ascending dose (MAD), randomized, placebo-controlled clinical trial of PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1)", stating that "[t]he partial clinical hold questions raised by FDA relate to
More news about: Pomerantz LLP
Mar 12, 2026, 09:01 ET MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035
fibrosis, and improved glucose control. Furthermore, in Phase 1a, 1b and 2a trials, vanoglipel was well tolerated in both healthy volunteers and those with T2DM. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.About MetaViaMetaVia
More news about: MetaVia Inc.
Mar 12, 2026, 04:58 ET ImmunoForge to Conduct Strategic Partnering at Bio-Europe Spring 2026
is currently in a Phase 2 clinical trial for Polymyositis (PM) and Dermatomyositis (DM) in South Korea. Recognizing its therapeutic potential, the U.S. FDA has granted Orphan Drug Designation (ODD) to PF1801 for PM, DM, and Duchenne Muscular Dystrophy (DMD). Additionally, PF1804 (pemziviptadil)
More news about: ImmunoForge Co., Ltd.
Mar 11, 2026, 12:01 ET Symmetry Sports Construction Completes New AstroTurf® 3DM 60 Installation at Abilene Christian University, Expanding Elite-Level Footprint Across Texas
March 11, 2026 /PRNewswire/ -- Symmetry Sports Construction, a trusted AstroTurf distributor and field builder, has completed a new AstroTurf® 3DM 60 installation at Abilene Christian University, providing ACU with a modern, high-performance field built to deliver elite performance season after
More news about: AstroTurf
Mar 11, 2026, 04:00 ET ARTHEx Biotech Granted FDA Fast Track Designation for ATX-01 for the Treatment of Myotonic Dystrophy Type 1 (DM1)
Dystrophy type 1 (DM1). ATX-01 is ARTHEx's investigational RNA therapeutic designed to address the underlying genetic cause of DM1, a highly disabling neuromuscular disorder with no known cure. "Receiving Fast Track Designation for ATX-01 is an important milestone for ARTHEx and the DM1 community,"
More news about: ARTHEx Biotech
Mar 06, 2026, 01:36 ET Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's National Medical Products Administration (NMPA) for Chronic Weight Management
far-reaching implications across multiple organ systems. Obesity related diseases encompass a broad spectrum of conditions including cardiovascular disease, T2DM, MASH, OSA and numerous other comorbidities. Lifestyle intervention remains the cornerstone of overweight and obesity management. When lifestyle modifications
More news about: Sciwind Biosciences Co., Ltd.
Mar 05, 2026, 10:25 ET DoubleLine Foresees Convergence Between Emerging and Developed Sovereign Credits
paper, titled "EM-DM Convergence: A Secular Trade on Deglobalization," is available here: https://doubleline.com/wp-content/uploads/DoubleLine_EM-DM-Convergence_February-2026.pdfLocal
More news about: DoubleLine
Mar 05, 2026, 08:41 ET DM20.ai Launches World's First Multi-Model AI Platform Exclusively for Direct Mail Performance Optimization
since 2016. That level of performance data and domain experience formed the foundation for the proprietary algorithm powering DM20.ai.Unlike generic marketing AI tools, DM20.ai was designed exclusively for the direct mail industry. The platform combines a performance algorithm built on structured
More news about: DirectMail2.0 LLC.
Feb 26, 2026, 16:02 ET Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
#138 M: Patient Journey Among Individuals with Myotonic Dystrophy Type 1 (DM1): a Patient and Caregiver Interview Study (March 9, 2026)#129 M: Experiences with Myotonic Dystrophy Type 1 (DM1) and Treatment with Del-desiran: Interviews with Participants in MARINA-OLE and their Caregivers
More news about: Avidity Biosciences, Inc.
Feb 25, 2026, 18:17 ET Samsung presenta la serie Galaxy S26: el teléfono Galaxy AI más intuitivo hasta la fecha
de mensajería de terceros, incluidos Samsung Messages, Google Messages, Google Chat, WhatsApp, WhatsApp Business, KakaoTalk, LINE, Signal, Instagram (DM), Tango, NTT Docomo Messages y KDDI Messages. Compartir fotos en Now Nudge funciona analizando el contenido de imágenes disponible. No se garantiza la
More news about: Samsung Mexico
Feb 25, 2026, 03:00 ET ARTHEx Biotech Announces Publication in The American Journal of Human Genetics Highlighting the Discovery and Preliminary Preclinical Profile of ATX-01 for Myotonic Dystrophy Type 1 (DM1)
strategies in DM1.ATX-01 is currently being evaluated in the ArthemiR™ study, which is a randomized, placebo-controlled, double-blind single (SAD) and multiple ascending dose (MAD) study evaluating ATX-01 in adults with DM1. ATX-01 has received Orphan Drug Designation for ATX-01 in DM1 from the US
More news about: ARTHEx Biotech
Feb 23, 2026, 08:00 ET Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly owned precision cardiology
More news about: Avidity Biosciences, Inc.
Feb 18, 2026, 17:00 ET The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
with DM1. Long-term data from the MARINA-OLE trial showed reversal of disease progression in people living with DM1 across multiple endpoints including video hand opening time (vHOT) as a measure of hand function and myotonia, muscle strength and activities of daily living when compared to END-DM1 natural
More news about: Avidity Biosciences, Inc.